Nuplazid meets primary endpoint in late-stage dementia-related psychosis HARMONY study -

Nuplazid meets primary endpoint in late-stage dementia-related psychosis HARMONY study
Information type: Media and commentaries
Source: DiabetesTeam
Specialities: Later life | Neurological disorders
Summary
In this study (n=392) patients had average baseline of moderate to severe psychosis as per the Scale for Assessment of Positive Symptoms-Hallucinations and Delusions (SAPS-H+D). Nuplazid patients saw their SAPS-H+D score improve by 63% and 75.2%, respectively.
UKMi comment
Nuplazid is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. In the US, Nuplazid is approved to treat psychosis related to Parkinson’s disease but failed to hit statistical significance in a Phase III schizophrenia trial. Nuplazid is not available in the EU and developmental status is unknown.
Related links: